In a recent paper involving NSCLC patients, clinical responses to gefitinib (an anti-EGF receptor agent) were shown to be correlated with HER2 overexpression/amplification in EGF receptor-positive patients (Cappuzzo et al, 2005). Here, ERBB2 is linked to non-small cell lung carcinoma.